Alnylam Pharmaceuticals (ALNY) EBT Margin Growth (5y) (2014 - 2026)
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) EBT Margin Growth (5y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9,916.00 |
| Mar 31, 2026 | 13,122.00 |
| Dec 31, 2025 | 15,680.00 |
| Sep 30, 2025 | 22,306.00 |
| Jun 30, 2025 | 16,578.00 |
| Mar 31, 2025 | 17,471.00 |
| Dec 31, 2024 | 35,315.00 |
| Sep 30, 2024 | 27,652.00 |
| Jun 30, 2024 | 48,702.00 |
| Mar 31, 2024 | 53,144.00 |
| Dec 31, 2023 | 97,225.00 |
| Sep 30, 2023 | 1.19 Mn |
| Jun 30, 2023 | 46,061.00 |
| Mar 31, 2023 | 59,114.00 |
| Dec 31, 2022 | 31,324.00 |
| Sep 30, 2022 | 56,551.00 |
| Jun 30, 2022 | 62,111.00 |
| Mar 31, 2022 | 45,364.00 |
| Dec 31, 2021 | 59,219.00 |
| Sep 30, 2021 | 65,646.00 |